Modified influenza virus for monitoring and improving vaccine efficiency (SJ-04-0033)

St. Jude Reference #SJ-04-0033


The inventors found that the conversion of serine at position 223 to asparagine (N223) in the HA protein of the H5N1 influenza virus increased the sensitivity of a hemagglutination inhibition (HI) assay in which this protein was used. This N223 change alters receptor specificity and/or antibody-antigen binding. The inclusion of the N223 residue in the HA proteins of diagnostic reference viruses may facilitate the evaluation of vaccine efficacy in humans.


Influenza, H5N1, hemagglutination inhibition assay

Granted patents or published applications

Issued, 4 US, 9 pending
Issued US Patents Nos. 7,871,626; 8,293,247; 8,574,592; 9,499,850.25

Related scientific references

Hoffmann E, Lipatov AS, Webby RJ, Govorkova EA, Webster RG., Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12915-20.

Licensing opportunities

We are currently looking for licensees in fields other than veterinary use. Contact:

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.